Day: January 13, 2025

Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 a.m. E.T. IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today provided an update on the Company’s key priorities for 2025, including plans to advance TP-04 for the potential treatment of Ocular Rosacea, another category-creating opportunity in eye care. “2024 was a groundbreaking year for Tarsus as we established XDEMVY as one of the most successful eye care launches to date. With consistent quarter-over-quarter revenue growth, rapid physician adoption, broad payer coverage to date, and continued...

Company is scheduled to break ground on the “SKY” Hangar at Skyborne Technology’s Costin Airport in the first quarter of 2025Skyborne Technology and AIG Joint ProjectWEWAHITCHKA and PORT ST JOE, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) — UAV Corp (OTC: UMAV), a leader in innovative manned and unmanned aerial vehicle (UAV) technologies is proud to share updates on its latest advancements in airship technology and its growing global presence. With several global contracts currently under negotiation, UAV Corp continues to position itself as a leader in sustainable aviation solutions. These agreements, represented by Letters of Intent (LOIs), outline additional contracts valued at a minimum of $105 million for a system of three DART Series (Detachable-Airship-Retractable Tether) airships.UMAV/Skyborne Technology’s...

With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today issued an open letter from Larry Jasinski, Chief Executive Officer, to shareholders highlighting the Company’s significant achievements in 2024 and outlining the key objectives for 2025. The full letter is published below. Dear Shareholders and other Stakeholders, From our founding in 2001, the Company has collectively poured its collaborative efforts into achieving our mission: To relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they...

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”), an emerging North American uranium and lithium exploration company, is pleased to announce that the Company has obtained a final order from the Supreme Court of British Columbia approving the proposed plan of arrangement (the “Arrangement”) under which the Company will spin-out its gold and silver properties located in Sierra County, New Mexico, United States (collectively, the “Winston Property”) to shareholders through Rio Grande Resources Ltd. (“Rio Grande”), a wholly-owned subsidiary of the Company. The Arrangement was previously approved by 99.86% of votes cast by Foremost shareholders (the “Shareholders”) at the annual general and special meeting of Shareholders held on December...

White Label Partnership Enters its 2nd Year SCHAUMBURG, IL, Jan. 13, 2025 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, is pleased to announce its white label partnership with CVS, powering their CVS Gift Card Exchange is now entering its 2nd year. The platform that enables CVS to accept unwanted gift cards for store e-credit is accessible here:https://cvs.cardcash.com. Ketan Thakker, Chief Executive Officer of Giftify, Inc., commented, “We are pleased to enter our second year working together with CVS in enabling their gift card exchange program. More and more retailers are aligning with our vision in that when they’re well-chosen,...

Achieves 35% year-over-year growth to 209,900 members on Jan. 1, showing how Medicare Advantage can be done right Announces year-end 2025 health plan membership of 225,000 to 231,000 and reiterates confidence in achieving consensus adjusted EBITDA of $40 million in 2025ORANGE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC), an award-winning Medicare Advantage (MA) company, today announced Jan. 1 health plan membership of approximately 209,900, representing a 35% year-over-year increase in health plan membership when compared to membership as of Jan. 1, 2024. Additionally, the company expects to have 225,000 to 231,000 health plan members as of Dec. 31, 2025, representing growth of approximately 22% to 25% relative to the midpoint of its year-end 2024 membership guidance provided on Oct. 29,...

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Bloom Investment Counsel, Inc. (the “Manager”), the manager of Bloom Select Income Fund (TSX: BLB.UN) (the “Fund”), announced today that the Fund will terminate on March 5, 2025 (the “Termination”). Despite the Fund’s positive performance since inception, the Board of Directors of the Manager has determined that the Termination is in the best interests of the Fund and of the unitholders of the Fund because of the Fund’s small size, which has increased the MER and reduced trading liquidity for the Fund’s unitholders. On or before March 19, 2025, the Fund will distribute to each unitholder, in cash, their pro-rata share of the net assets of the Fund after all liabilities of the Fund have been paid or provided for. An application for voluntary delisting of the Fund’s units from the TSX has...

Study to be conducted under $3.6 million NIH grant  DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar Medical’s Selective Cytopheretic Device (SCD-ADULT) in reducing inflammation in adult patients with acute heart failure with worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting a left ventricular assist device (LVAD) implantation. This feasibility study is expected to enroll 20 patients at up to five clinical sites and will be...

Petah Tikvah, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology leader in advanced transportation safety solutions, is pleased to announce a new distribution agreement with uniSmart Vertriebs GmbH (“uniSmart”), a prominent German-based distributor specializing in fleet safety and technology integration. uniSmart, headquartered in Wendendelstein, provides solutions for logistics and transportation companies across Germany and abroad. The company resells, installs, and provides support for advanced fleet management and safety systems, including Webfleet technology, for a variety of fleet sizes and industries. uniSmart’s client base includes major national German transport operators and many medium-sized fleets. Mr. Ori Gilboa, CEO of SaverOne, commented, “We continue our strong...